Overview

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Status:
Recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

Early-stage Clinical Study of mesothelin-specific Chimericantigen Receptor T Cells (LD013) in Subjects With Refractory or Relapsed mesothelin-positive Ovarian Cancer

Phase:

N/A

Details

Lead Sponsor:

Weijia Fang, MD

Collaborator:

Nanjing Blue Shield Biotech Co.,Ltd